In a meeting with a host of Big Pharma execs last week, President Trump urged them to build plants and manufacture drugs in the U.S. Now a new U.S. plant has been announced but instead of coming from the invitees, it is being built by an Indian drugmaker which cited the administration’s attitude as a motivating factor.
In this week's FiercePharmaAsia wrap-up, Takeda has offered $5.2 billion to buy Ariad and made a $125 deal with Maverick on T-cell therapy R&D, Valeant sold Dendreon to a Chinese company for $820 million, and more.
India’s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in Portugal which it says will make it the largest generics manufacturer in that country.
Twenty states have unveiled a civil lawsuit accusing half a dozen drugmakers, including Mylan, Teva and Heritage, with generic drug price fixing just a day after the DOJ filed charges against two Heritage execs.
Scientists have been saying for years that polluting pharma plants are directly contributing to the spread of antibiotic resistance. Now, it looks as if they could have hard evidence in India, the world's biggest antibiotic producer.